Bojie Wang
1. No, it wasn’t. Because developing countries, such as India, although large by population, were characterized by low per capita gross domestic product (GDP). Typically, health care expenditures accounted for a very small share of GDP, and health insurance was not commonly available. Governments and large corporations extended health coverage, including prescription drug coverage, to their workers. In the years before and following India’s independence in 1947, the country had no indigenous capability to produce pharmaceuticals, and was dependent on imports.
2. No, it wasn’t. I think partnership is a good thing. Cause the partnership can produce more energy. It can have more advanced technology and much more resource etc.
3. No, it wasn’t. Cause the pharmaceutical industry continued to grow through 1990s. In 2001, worldwide retail sales were expected to increase 10 percent to about US$350 billion. There was a consolidation trend in the industry with ongoing mergers and acquisitions reshaping the industry. In addition, the partnerships between pharmaceutical and biotechnology companies were growing rapidly.
4. Yes, it was. Lilly was investigating the possibility of extending its operations to include generics. Following the launch of the Indian JV, Lilly and Ranbaxy, entered into two other agreements related to generics, one in India to focus on manufacturing generics, and the other in the United States to focus on the marketing of generics. However, within less than a year, Lilly made a strategic decision not to enter the generics market and the two parties agreed to terminate the JV agreements related to the generics.
5. Yes, it was. In 1999, Dr. Singh handed over the reins of the company to Brar, and later the same year, Ranbaxy lost this visionary leader due to an untimely death. Brar continued Singh’s vision to keep Ranbaxy in a
